CRISPR Therapeutics AG
GB ˙ LSE
51,84 USD ↓ -4,90 (-8,64%)
2026-06-05
PREZZO DELLE AZIONI
SecurityGB:0VRQ / CRISPR Therapeutics AG
InstitutionSquarepoint Ops LLC
Latest Disclosed Ownership153,575 shares
Latest Disclosed Value $ 7,305,563
Squarepoint Ops LLC ownership in 0VRQ / CRISPR Therapeutics AG

On May 15, 2026 - Squarepoint Ops LLC filed a 13F-HR form disclosing ownership of 153,575 shares of CRISPR Therapeutics AG (GB:0VRQ) valued at $7,199,596 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 581,108 shares of CRISPR Therapeutics AG. This represents a change in shares of -73.57% during the quarter. The current value of the position is $7,961,328 USD.

Squarepoint Ops LLC has a history of taking positions in derivatives of the underlying security (0VRQ) in the form of stock options. The firm currently holds call options representing 9,900 of underlying shares valued at $470,943 USD and put options representing 10,200 of underlying shares valued at $485,214 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

GB:0VRQ / CRISPR Therapeutics AG Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 153,575 -427,533 -73.57 7,306 -76.03 0.0086
2026-02-13 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 581,108 581,108 30,473 0.0324
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -30,278 -100.00 0 -100.00
2025-08-27 2025-06-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 30,278 -42,746 -58.54 1,473 -40.76 0.0015
2025-08-14 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 30,278 -42,746 1,473 0.0015
2025-08-27 2025-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 73,024 -93,115 -56.05 2,485 -62.00 0.0030
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 73,024 -93,115 2,485 0.0030
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 166,139 -82,840 -33.27 6,539 -44.10 0.0064
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 248,979 -19,844 -7.38 11,697 -19.44 0.0183
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 268,823 -5,207 -1.90 14,519 -22.26 0.0240
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 274,030 146,672 115.17 18,678 134.28 0.0321
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 127,358 -17,719 -12.21 7,973 21.06 0.0151
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 145,077 17,665 13.86 6,585 -7.93 0.0163
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 127,412 -3,506 -2.68 7,153 20.79 0.0219
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 130,918 -35,516 -21.34 5,921 -12.48 0.0241
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 166,434 96,783 138.95 6,766 48.62 0.0267
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 69,651 69,651 4,552 0.0230
2021-11-15 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -5,400 -100.00 0 -100.00
2021-08-16 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 5,400 -6,452 -54.44 874 -39.47 0.0033
2021-05-17 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 11,852 6,797 134.46 1,444 86.56 0.0085
2021-02-16 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 5,055 5,055 774 0.0058
2020-08-14 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -13,533 -100.00 0 -100.00
2020-05-15 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 13,533 -43,352 -76.21 574 -83.43 0.0147
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 56,885 56,885 3,465 0.0206
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -6,348 -100.00 0 -100.00
2019-08-14 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 6,348 494 8.44 299 43.06 0.0029
2019-05-15 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 5,854 -14,496 -71.23 209 -64.03 0.0022
2019-02-14 2018-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 20,350 20,350 581 0.0068
2018-08-14 2018-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -7,919 -100.00 0 -100.00
2018-05-15 2018-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 7,919 7,919 362 0.0057
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 9,900 -86.15 471 -87.46 n/a n/a n/a
2026-02-13 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 71,500 -33.55 3,749 -46.24 n/a n/a n/a
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 107,600 905.61 6,974 1,240.96 n/a n/a n/a
2025-08-27 2025-06-30 13F/A CRISPR THERAPEUTICS NAMEN AKT Call 10,700 -25.17 520 7.00 n/a n/a n/a
2025-08-14 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 10,700 520 n/a n/a n/a
2025-08-27 2025-03-31 13F/A CRISPR THERAPEUTICS NAMEN AKT Call 14,300 -64.95 487 -69.72 n/a n/a n/a
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 14,300 487 n/a n/a n/a
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 40,800 248.72 1,606 192.35 n/a n/a n/a
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 11,700 -0.85 550 -13.81 n/a n/a n/a
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 11,800 -26.25 637 -41.56 n/a n/a n/a
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 16,000 -16.23 1,091 -8.79 n/a n/a n/a
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 19,100 1,196 n/a n/a n/a
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 10,000 -9.09 561 12.88 n/a n/a n/a
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 11,000 -65.30 498 -61.41 n/a n/a n/a
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 31,700 -0.94 1,289 -38.40 n/a n/a n/a
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 32,000 2,091 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 10,200 -79.72 485 -81.61 n/a n/a n/a
2026-02-13 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 50,300 -22.85 2,638 -37.59 n/a n/a n/a
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 65,200 285.80 4,226 413.99 n/a n/a n/a
2025-08-27 2025-06-30 13F/A CRISPR THERAPEUTICS NAMEN AKT Put 16,900 -21.76 822 11.84 n/a n/a n/a
2025-08-14 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 16,900 822 n/a n/a n/a
2025-08-27 2025-03-31 13F/A CRISPR THERAPEUTICS NAMEN AKT Put 21,600 -68.14 735 -72.45 n/a n/a n/a
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 21,600 735 n/a n/a n/a
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 67,800 242.42 2,669 186.88 n/a n/a n/a
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 19,800 -33.11 930 -41.80 n/a n/a n/a
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 29,600 -46.38 1,599 -57.52 n/a n/a n/a
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 55,200 72.50 3,762 87.82 n/a n/a n/a
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 32,000 -55.49 2,003 -38.61 n/a n/a n/a
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 71,900 -37.64 3,264 -49.58 n/a n/a n/a
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 115,300 -6.26 6,473 16.34 n/a n/a n/a
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 123,000 -6.68 5,563 3.85 n/a n/a n/a
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 131,800 0.00 5,358 -37.80 n/a n/a n/a
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 131,800 8,613 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.